Mass Spectrometry as a Quantitative Proteomic Analysis Tool for the Search for Temporal Lobe Epilepsy Biomarkers: A Systematic Review

Temporal lobe epilepsy (TLE) is the most common form of epilepsy in adults. Tissue reorganization at the site of the epileptogenic focus is accompanied by changes in the expression patterns of protein molecules. The study of mRNA and its corresponding proteins is crucial for understanding the pathogenesis of the disease. Protein expression profiles do not always directly correlate with the levels of their transcripts; therefore, it is protein profiling that is no less important for understanding the molecular mechanisms and biological processes of TLE. The study and annotation of proteins that are statistically significantly different in patients with TLE is an approach to search for biomarkers of this disease, various stages of its development, as well as a method for searching for specific targets for the development of a further therapeutic strategy. When writing a systematic review, the following aggregators of scientific journals were used: MDPI, PubMed, ScienceDirect, Springer, and Web of Science. Scientific articles were searched using the following keywords: “proteomic”, “mass-spectrometry”, “protein expression”, “temporal lobe epilepsy”, and “biomarkers”. Publications from 2003 to the present have been analyzed. Studies of brain tissues, experimental models of epilepsy, as well as biological fluids, were analyzed. For each of the groups, aberrantly expressed proteins found in various studies were isolated. Most of the studies omitted important characteristics of the studied patients, such as: duration of illness, type and response to therapy, gender, etc. Proteins that overlap across different tissue types and different studies have been highlighted: DPYSL, SYT1, STMN1, APOE, NME1, and others. The most common biological processes for them were the positive regulation of neurofibrillary tangle assembly, the regulation of amyloid fibril formation, lipoprotein catabolic process, the positive regulation of vesicle fusion, the positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway, removal of superoxide radicals, axon extension, and the regulation of actin filament depolymerization. MS-based proteomic profiling for a relevant study must accept a number of limitations, the most important of which is the need to compare different types of neurological and, in particular, epileptic disorders. Such a criterion could increase the specificity of the search work and, in the future, lead to the discovery of biomarkers for a particular disease.

[1]  C. Li,et al.  The Study of Overexpression of Peroxiredoxin-2 Reduces MPP+-Induced Toxicity in the Cell Model of Parkinson’s Disease , 2023, Neurochemical Research.

[2]  D. Dmitrenko,et al.  Biomarkers of Drug Resistance in Temporal Lobe Epilepsy in Adults , 2023, Metabolites.

[3]  Daniel W. Summers,et al.  Membrane association is required for Stmn2-mediated axon protection , 2022, bioRxiv.

[4]  J. Boice,et al.  Radiation and CNS effects: summary of evidence from a recent symposium of the Radiation Research Society , 2022, International journal of radiation biology.

[5]  M. Ropacka-Lesiak,et al.  Blood-Brain Barrier Disintegration in Growth-Restricted Fetuses with Brain Sparing Effect , 2022, International journal of molecular sciences.

[6]  G. Žoldák,et al.  Different Approaches for the Profiling of Cancer Pathway-Related Genes in Glioblastoma Cells , 2022, International journal of molecular sciences.

[7]  Jing Ding,et al.  Neuropilin-2 Signaling Modulates Mossy Fiber Sprouting by Regulating Axon Collateral Formation Through CRMP2 in a Rat Model of Epilepsy , 2022, Molecular Neurobiology.

[8]  Ye Lin,et al.  Retinal neurodegeneration in a mouse model of green-light-induced myopia. , 2022, Experimental eye research.

[9]  Zhao Wang,et al.  Proteomic Analysis Reveals the Vital Role of Synaptic Plasticity in the Pathogenesis of Temporal Lobe Epilepsy , 2022, Neural plasticity.

[10]  A. Hosseini,et al.  The role of astrocytes in epileptic disorders , 2022, Physiological reports.

[11]  S. Bhatia,et al.  Polyphenols inhibiting MAPK signalling pathway mediated oxidative stress and inflammation in depression. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  K. Kuter,et al.  Beyond the GFAP-Astrocyte Protein Markers in the Brain , 2021, Biomolecules.

[13]  R. Franklin,et al.  Diversity of Reactive Astrogliosis in CNS Pathology: Heterogeneity or Plasticity? , 2021, Frontiers in Cellular Neuroscience.

[14]  P. Hartikainen,et al.  GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[15]  G. He,et al.  DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma , 2021, World Journal of Surgical Oncology.

[16]  K. Park,et al.  Temporal lobe epilepsy with or without hippocampal sclerosis: Structural and functional connectivity using advanced MRI techniques , 2021, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[17]  K. Gardiner,et al.  Altered Protein Profiles During Epileptogenesis in the Pilocarpine Mouse Model of Temporal Lobe Epilepsy , 2021, Frontiers in Neurology.

[18]  M. Çalık,et al.  Investigation on Acute Phase Reactants and Oxidant - Antioxidant Parameters in Patients Diagnosed as Having Generalized Tonic Clonic Type Epilepsy on Antiepileptic Monotherapy and Polytherapy , 2021 .

[19]  E. Kumlien,et al.  Quantitative proteomic analysis to identify differentially expressed proteins in patients with epilepsy , 2021, Epilepsy Research.

[20]  K. Khajeh,et al.  Proteomic profiling of the rat hippocampus from the kindling and pilocarpine models of epilepsy: potential targets in calcium regulatory network , 2021, Scientific Reports.

[21]  H. Potter,et al.  Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease , 2021, Neurobiology of Aging.

[22]  Li Feng,et al.  iTRAQ-Based Proteomic Analysis of Dentate Gyrus in Temporal Lobe Epilepsy With Hippocampal Sclerosis , 2021, Frontiers in Neurology.

[23]  V. Lennon,et al.  The complement C3‐C3aR pathway mediates microglia–astrocyte interaction following status epilepticus , 2020, Glia.

[24]  Chen Zhang,et al.  iTRAQ‐based proteomic analysis of the hippocampus of pentylenetetrazole‐kindled epileptic rats , 2020, International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience.

[25]  M. Movahedi,et al.  Identification of Serum Biomarkers for Differentiating Epileptic Seizures from Psychogenic Attacks Using a Proteomic Approach; a Comparative study , 2020, Archives of academic emergency medicine.

[26]  Tiechao Jiang,et al.  TMT-Based Proteomic Analysis of Plasma from Children with Rolandic Epilepsy , 2020, Disease markers.

[27]  X. Bao,et al.  Proteomic profiling of sclerotic hippocampus revealed dysregulated packaging of vesicular neurotransmitters in temporal lobe epilepsy , 2020, Epilepsy Research.

[28]  M. Sabbagh,et al.  Effect of ApoE isoforms on mitochondria in Alzheimer disease , 2020, Neurology.

[29]  K. Fukuchi,et al.  TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease , 2020, Frontiers in Immunology.

[30]  G. O’Keeffe,et al.  STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5 , 2020, iScience.

[31]  S. Sisodiya,et al.  Granule Cell Dispersion in Human Temporal Lobe Epilepsy: Proteomics Investigation of Neurodevelopmental Migratory Pathways , 2020, Frontiers in Cellular Neuroscience.

[32]  M. Bartos,et al.  Dentate gyrus circuits for encoding, retrieval and discrimination of episodic memories , 2020, Nature Reviews Neuroscience.

[33]  F. Pallardó,et al.  Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age , 2019, Molecular Neurobiology.

[34]  C. Taghibiglou,et al.  Nuclear accumulation of GAPDH, GluA2 and p53 in post-mortem substantia nigral region of patients with Parkinson’s disease , 2019, Neuroscience Letters.

[35]  F. Onat,et al.  Relationships between astrocytes and absence epilepsy in rat: An experimental study , 2019, Neuroscience Letters.

[36]  C. Rodrigues,et al.  Ablation of RIP3 protects from dopaminergic neurodegeneration in experimental Parkinson’s disease , 2019, Cell Death & Disease.

[37]  W. Swardfager,et al.  The complement cascade in Alzheimer’s disease: a systematic review and meta-analysis , 2019, Molecular Psychiatry.

[38]  C. Subhramanyam,et al.  Microglia-mediated neuroinflammation in neurodegenerative diseases. , 2019, Seminars in cell & developmental biology.

[39]  Joseph S. Briguglio,et al.  Synaptotagmin 1 clamps synaptic vesicle fusion in mammalian neurons independent of complexin , 2019, Nature Communications.

[40]  V. Vorobyov,et al.  Detrimental and synergistic role of epilepsy – Alzheimer’s disease risk factors , 2019, Neural regeneration research.

[41]  J. Tepper,et al.  Neuropilin 2 Signaling Mediates Corticostriatal Transmission, Spine Maintenance, and Goal-Directed Learning in Mice , 2019, The Journal of Neuroscience.

[42]  A. Falcão,et al.  ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches. , 2019, Pharmacological research.

[43]  A. Das Disease association of human tumor suppressor genes , 2019, Molecular Genetics and Genomics.

[44]  J. Sander,et al.  Epilepsy in adults , 2019, The Lancet.

[45]  I. Jialal,et al.  Physiology, Acute Phase Reactants , 2019 .

[46]  D. Reddy,et al.  Neuroimaging Biomarkers of Experimental Epileptogenesis and Refractory Epilepsy , 2019, International journal of molecular sciences.

[47]  N. Fitz,et al.  The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives , 2018, International journal of molecular sciences.

[48]  Simone Lista,et al.  Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic , 2018, Nature Reviews Neurology.

[49]  J. Kassubek,et al.  Serum GFAP as a biomarker for disease severity in multiple sclerosis , 2018, Scientific Reports.

[50]  E. Yacubian,et al.  Altered Proteins in the Hippocampus of Patients with Mesial Temporal Lobe Epilepsy , 2018, Pharmaceuticals.

[51]  Ingo Borggraefe,et al.  SYT1-associated neurodevelopmental disorder: a case series , 2018, Brain : a journal of neurology.

[52]  A. Ikeda,et al.  Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region , 2018, Front. Pharmacol..

[53]  K. Hamandi,et al.  Complement system biomarkers in epilepsy , 2018, Seizure.

[54]  J. Loeb,et al.  Proteomic analysis of human epileptic neocortex predicts vascular and glial changes in epileptic regions , 2018, PloS one.

[55]  Y. Fujii,et al.  Pathophysiological Characteristics Associated With Epileptogenesis in Human Hippocampal Sclerosis , 2018, EBioMedicine.

[56]  A. Becker,et al.  Review: Animal models of acquired epilepsy: insights into mechanisms of human epileptogenesis , 2018, Neuropathology and applied neurobiology.

[57]  V. Cavaliere,et al.  Extracellular NME proteins: a player or a bystander? , 2018, Laboratory Investigation.

[58]  Hui Shen,et al.  The antiepileptic drug levetiracetam promotes neuroblast differentiation and expression of superoxide dismutase in the mouse hippocampal dentate gyrus via PI3K/Akt signalling , 2018, Neuroscience Letters.

[59]  M. Nadai,et al.  Effect of carbamazepine on expression of UDP-glucuronosyltransferase 1A6 and 1A7 in rat brain. , 2017, Drug metabolism and pharmacokinetics.

[60]  Linda J. C. van Waalwijk van Doorn,et al.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[61]  R. Kukreti,et al.  In Vitro Assessment of the Effect of Antiepileptic Drugs on Expression and Function of ABC Transporters and Their Interactions with ABCC2 , 2017, Molecules.

[62]  A. Abdel-Moneim,et al.  Gallic acid and p-coumaric acid attenuate type 2 diabetes-induced neurodegeneration in rats , 2017, Metabolic Brain Disease.

[63]  Ben C. Collins,et al.  Quantitative proteomics: challenges and opportunities in basic and applied research , 2017, Nature Protocols.

[64]  R. Krause,et al.  A systems level analysis of epileptogenesis-associated proteome alterations , 2017, Neurobiology of Disease.

[65]  O. Firuzi,et al.  Oxidative Stress and Antioxidants in Neurological Diseases: Is There Still Hope? , 2017, Current drug targets.

[66]  Hui Yang,et al.  Differentially expressed proteins underlying childhood cortical dysplasia with epilepsy identified by iTRAQ proteomic profiling , 2017, PloS one.

[67]  K. Blennow,et al.  The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.

[68]  R. Aebersold,et al.  On the Dependency of Cellular Protein Levels on mRNA Abundance , 2016, Cell.

[69]  A. Vlahou,et al.  High-Throughput LC-MS/MS Proteomic Analysis of a Mouse Model of Mesiotemporal Lobe Epilepsy Predicts Microglial Activation Underlying Disease Development. , 2016, Journal of proteome research.

[70]  A. Vezzani,et al.  Proteomic profiling of epileptogenesis in a rat model: Focus on inflammation , 2016, Brain, Behavior, and Immunity.

[71]  Xia Zhang,et al.  Role of neuroinflammation in neurodegenerative diseases (Review) , 2016, Molecular medicine reports.

[72]  M. Disatnik,et al.  Impaired GAPDH-induced mitophagy contributes to the pathology of Huntington’s disease , 2015, EMBO molecular medicine.

[73]  Kimberly J. Jenko,et al.  Neuroinflammation in Temporal Lobe Epilepsy Measured Using Positron Emission Tomographic Imaging of Translocator Protein. , 2015, JAMA neurology.

[74]  K. Staley Molecular mechanisms of epilepsy , 2015, Nature Neuroscience.

[75]  I. Fournier,et al.  Human temporal lobe epilepsy analyses by tissue proteomics , 2014, Hippocampus.

[76]  E. Cavalheiro,et al.  Decreased expression of proteins involved in energy metabolism in the hippocampal granular layer of rats submitted to the pilocarpine epilepsy model , 2014, Neuroscience Letters.

[77]  D. Janigro,et al.  Inflammatory pathways of seizure disorders , 2014, Trends in Neurosciences.

[78]  G. Biagini,et al.  Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic? , 2014, Current medicinal chemistry.

[79]  H. Tanaka,et al.  Phosphorylation of Dpsyl2 (CRMP2) and Dpsyl3 (CRMP4) is required for positioning of caudal primary motor neurons in the zebrafish spinal cord , 2013, Developmental neurobiology.

[80]  T. Südhof,et al.  Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle , 2013, Neuron.

[81]  A. Vezzani,et al.  Immunity Activation in Brain Cells in Epilepsy: Mechanistic Insights and Pathological Consequences , 2013, Neuropediatrics.

[82]  L. Hillered,et al.  Identification of Injury Specific Proteins in a Cell Culture Model of Traumatic Brain Injury , 2013, PloS one.

[83]  E. Hol,et al.  GFAP Isoforms in Adult Mouse Brain with a Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of Alzheimer Disease , 2012, PloS one.

[84]  M. Fukata,et al.  Leucine‐rich glioma inactivated 1 (Lgi1), an epilepsy‐related secreted protein, has a nuclear localization signal and localizes to both the cytoplasm and the nucleus of the caudal ganglionic eminence neurons , 2012, The European journal of neuroscience.

[85]  D. Macêdo,et al.  Oxidative Stress and Epilepsy: Literature Review , 2012, Oxidative medicine and cellular longevity.

[86]  E. Chapman,et al.  Uncoupling the roles of synaptotagmin I as a dual Ca2+ sensor during endo- and exocytosis of synaptic vesicles , 2011, Nature Neuroscience.

[87]  A. Pitkänen,et al.  Mechanisms of epileptogenesis and potential treatment targets , 2011, The Lancet Neurology.

[88]  P. Horn,et al.  Evaluating reference genes to normalize gene expression in human epileptogenic brain tissues. , 2010, Biochemical and biophysical research communications.

[89]  Maria Thom,et al.  Reliability of patterns of hippocampal sclerosis as predictors of postsurgical outcome , 2010, Epilepsia.

[90]  R. Huganir,et al.  Secreted Semaphorins Control Spine Distribution and Morphogenesis in the Postnatal CNS , 2009, Nature.

[91]  Yuquan Wei,et al.  A review of current applications of mass spectrometry for neuroproteomics in epilepsy. , 2009, Mass spectrometry reviews.

[92]  E. Blalock,et al.  Decreased number of interneurons and increased seizures in neuropilin 2 deficient mice: Implications for autism and epilepsy , 2009, Epilepsia.

[93]  Pat Levitt,et al.  The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. , 2009, The Journal of clinical investigation.

[94]  Jie Yuan,et al.  Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy , 2009, Brain Research.

[95]  Ying Zhang,et al.  Comparative Proteomics and Correlated Signaling Network of Rat Hippocampus in the Pilocarpine Model of Temporal Lobe Epilepsy , 2007 .

[96]  Jens M. Rick,et al.  Quantitative mass spectrometry in proteomics: a critical review , 2007, Analytical and bioanalytical chemistry.

[97]  F. L. D. Silva,et al.  Complement activation in experimental and human temporal lobe epilepsy , 2007, Neurobiology of Disease.

[98]  Lin-Tao Zhou,et al.  Febrile seizures are associated with mutation of seizure‐related (SEZ) 6, a brain‐specific gene , 2007, Journal of neuroscience research.

[99]  Wei Yang,et al.  Proteomic analysis and comparison of the biopsy and autopsy specimen of human brain temporal lobe , 2006, Proteomics.

[100]  C. Baumgartner,et al.  Aberrant expression of cytoskeleton proteins in hippocampus from patients with mesial temporal lobe epilepsy , 2006, Amino Acids.

[101]  R. Cumming,et al.  Amyloid‐β induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease , 2005 .

[102]  Andrey Rzhetsky,et al.  Emergent behavior of growing knowledge about molecular interactions , 2005, Nature Biotechnology.

[103]  M. Mann,et al.  Mass spectrometry–based proteomics turns quantitative , 2005, Nature chemical biology.

[104]  G. Cascino Temporal Lobe Epilepsy: More than Hippocampal Pathology , 2005, Epilepsy currents.

[105]  S. Snyder,et al.  S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding , 2005, Nature Cell Biology.

[106]  P. Lescuyer,et al.  Identification of post‐mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration , 2004, Proteomics.

[107]  Y. Kwak,et al.  Proteomic analysis of human cerebral cortex in epileptic patients , 2004, Experimental & Molecular Medicine.

[108]  Maria Helena Pimentel,et al.  Comparative , 1986, American Political Science Review.

[109]  Thomas Bourgeron,et al.  Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism , 2003, Nature Genetics.

[110]  H. Haapasalo,et al.  Expression of Antioxidant Enzymes in Astrocytic Brain Tumors , 2003, Brain pathology.

[111]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[112]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[113]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[114]  D. Butterfield,et al.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase‐related protein 2, α‐enolase and heat shock cognate 71 , 2002, Journal of neurochemistry.

[115]  C. Dodia,et al.  1-Cys Peroxiredoxin, a Bifunctional Enzyme with Glutathione Peroxidase and Phospholipase A2 Activities* , 2000, The Journal of Biological Chemistry.

[116]  T. Babb,et al.  The pathogenic and progressive features of chronic human hippocampal epilepsy , 1996, Epilepsy Research.

[117]  T L Babb,et al.  Influence of the type of initial precipitating injury and at what age it occurs on course and outcome in patients with temporal lobe seizures. , 1995, Journal of neurosurgery.

[118]  Yan Zhang,et al.  Acute phase reactant serum amyloid A in inflammation and other diseases. , 2019, Advances in clinical chemistry.

[119]  P. Meleady Two-Dimensional Gel Electrophoresis and 2D-DIGE. , 2018, Methods in molecular biology.

[120]  A. Blom,et al.  C4b-binding protein: The good, the bad and the deadly. Novel functions of an old friend. , 2016, Immunology letters.

[121]  L. Paša-Tolić,et al.  High-throughput proteomics. , 2014, Annual review of analytical chemistry.

[122]  E. Cavalheiro,et al.  Granule cell dispersion is not a predictor of surgical outcome in temporal lobe epilepsy with mesial temporal sclerosis. , 2013, Clinical neuropathology.

[123]  A. Kiliçarslan,et al.  Acute Phase Reactants , 2013 .

[124]  J. Clelland Genomics, proteomics, and the nervous system , 2011 .

[125]  D. Sizova Protein Expression Profile of Alzheimer’s Disease Mouse Model Generated by Difference Gel Electrophoresis (DIGE) Approach , 2011 .

[126]  D. Tomassoni,et al.  Biomarkers of glial cell proliferation and differentiation in culture. , 2010, Frontiers in bioscience.

[127]  R. Pumain,et al.  A key glycolytic enzyme plays a dual role in GABAergic neurotransmission and in human epilepsy. , 2006, Critical Reviews in Neurobiology.

[128]  S. Patterson How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See? , 2004 .